• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.

作者信息

Mohan Lal Bhavesh, Pandey Toshali, Alzubi Marah, Alrawabdeh Jawad, Shaughnessy John, Zhan Fenghuang, Siegel Eric R, Schinke Carolina, Thanendrarajan Sharmilan, Zangari Maurizio, van Rhee Frits, Al Hadidi Samer

机构信息

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Faculty of Medicine, University of Jordan, Amman, Jordan.

出版信息

Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02607-0.

DOI:10.1038/s41409-025-02607-0
PMID:40246944
Abstract
摘要

相似文献

1
Chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma: a real-world experience.嵌合抗原受体T细胞疗法治疗复发/难治性多发性骨髓瘤：一项真实世界经验
Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02607-0.
2
CAR-T Therapy in Relapsed Refractory Multiple Myeloma.嵌合抗原受体 T 细胞疗法在复发/难治性多发性骨髓瘤中的应用。
Curr Med Chem. 2024;31(27):4362-4382. doi: 10.2174/0109298673268932230920063933.
3
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.在 LEGEND-2 研究中，接受 LCAR-B38M 嵌合抗原受体 T 细胞治疗的复发/难治性多发性骨髓瘤伴髓外疾病患者获得 5 年无疾病进展缓解：一例报告。
J Med Case Rep. 2022 Dec 11;16(1):459. doi: 10.1186/s13256-022-03636-9.
4
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.真实世界数据下复发/难治性多发性骨髓瘤的治疗选择：ASH 2023 年会 podcast 关键数据
Adv Ther. 2024 Aug;41(8):3017-3027. doi: 10.1007/s12325-024-02842-9. Epub 2024 Apr 20.
5
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.嵌合抗原受体T细胞疗法后复发/难治性多发性骨髓瘤患者的特发性血小板减少性紫癜治疗
Regen Ther. 2020 May 15;14:271-274. doi: 10.1016/j.reth.2020.03.005. eCollection 2020 Jun.
6
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.嵌合抗原受体 T 细胞疗法治疗复发/难治性免疫球蛋白 D 多发性骨髓瘤的疗效和安全性。
Transplant Cell Ther. 2021 Mar;27(3):273.e1-273.e5. doi: 10.1016/j.jtct.2020.12.017. Epub 2020 Dec 19.
7
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
8
Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies.复发或难治性多发性骨髓瘤患者且符合B细胞成熟抗原靶向治疗条件者的疾病负担
Future Oncol. 2025 Jul;21(17):2155-2165. doi: 10.1080/14796694.2025.2514399. Epub 2025 Jun 5.
9
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.法国早期全国范围内的 idecabtagene vicleucel 嵌合抗原受体 T 细胞治疗复发/难治性多发性骨髓瘤患者的经验（FENIX）：来自 DESCAR-T 登记处的真实世界 IFM 研究。
Br J Haematol. 2024 Sep;205(3):990-998. doi: 10.1111/bjh.19505. Epub 2024 May 15.
10
Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.嵌合抗原受体T细胞（CAR-T细胞）疗法治疗原发性和继发性中枢神经系统淋巴瘤：文献系统综述
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):15-21. doi: 10.1016/j.clml.2022.09.008. Epub 2022 Oct 7.

本文引用的文献

1
French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.法国早期全国范围内的 idecabtagene vicleucel 嵌合抗原受体 T 细胞治疗复发/难治性多发性骨髓瘤患者的经验（FENIX）：来自 DESCAR-T 登记处的真实世界 IFM 研究。
Br J Haematol. 2024 Sep;205(3):990-998. doi: 10.1111/bjh.19505. Epub 2024 May 15.
2
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.靶向多发性骨髓瘤患者中的B细胞成熟抗原：当前观点
Onco Targets Ther. 2023 Jun 20;16:441-464. doi: 10.2147/OTT.S370880. eCollection 2023.
3
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
4
Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States.意图很重要：idecabtagene vicleucel在美国使用的现实世界适用性
J Clin Oncol. 2023 Jul 10;41(20):3657-3658. doi: 10.1200/JCO.23.00226. Epub 2023 May 26.
5
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
6
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.列入接受靶向BCMA的商业化嵌合抗原受体T细胞（CAR-T）疗法的复发难治性多发性骨髓瘤患者的临床结局
Bone Marrow Transplant. 2023 Apr;58(4):443-445. doi: 10.1038/s41409-022-01905-1. Epub 2022 Dec 22.
7
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.西达基奥仑赛治疗既往接受过其他 BCMA 靶向药物治疗的进展性多发性骨髓瘤患者的疗效和安全性。
Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526.
8
MRD in multiple myeloma: does CR really matter?多发性骨髓瘤中的微小残留病灶：完全缓解真的重要吗？
Blood. 2022 Dec 8;140(23):2423-2428. doi: 10.1182/blood.2022016170.
9
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.KarMMa-RW：idecabtagene vicleucel 与复发/难治性多发性骨髓瘤真实世界结局的比较。
Blood Cancer J. 2021 Jun 18;11(6):116. doi: 10.1038/s41408-021-00507-2.
10
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.